The global biopharmaceutical industry's race to secure next-generation oncology assets has reached an extraordinary level of intensity. For years, antibody-drug conjugates (ADCs)—which combine the targeting precision of monoclonal antibodies with the cell-killing potency of cytotoxic payloads—have driven billions of dollars in licensing deals and acquisitions. Yet, as rivals like Pfizer (via its $43 billion Seagen acquisition), AbbVie (via ImmunoGen for $10.1 billion), and AstraZeneca built multi-billion-dollar ADC franchises, Novartis remained a prominent holdout. Instead, the Swiss biopharma giant chose to build its precision-oncology platform around radioligand therapies (RLTs) and CAR-T cell therapies.
That strategic isolation ended on July 6, 2026, when Novartis announced an agreement to acquire London-based biotechnology specialist Myricx Bio for a total deal value of up to $1.5 billion. By securing Myricx’s novel N-myristoyltransferase inhibitor (NMTi) payload platform and its lead solid-tumor assets, Novartis has officially entered the ADC field.
To contextualize this transaction within the broader oncology landscape, we analyzed the deal structure, the biochemical differentiation of the NMTi payload, the target assets, and Novartis's broader 2026 deal spree. This deal marks a critical pivot for Novartis, moving it from a pure-play RLT leader to a diversified precision-oncology player, while introducing a highly differentiated payload class to a competitive landscape dominated by topoisomerase-1 (TOPO-1) and tubulin inhibitors.
What are the financial terms of the Novartis-Myricx deal?
The transaction is structured to mitigate early-stage clinical risk while providing Myricx’s backers with a substantial cash payout. Under the terms of the agreement, Novartis will acquire 100% of Myricx Bio’s equity for:
- Upfront Cash Payment: $1.1 billion in cash, paid upon the closing of the transaction.
- Potential Milestones: Up to $400 million in additional payments, contingent upon the achievement of specific development, regulatory, and commercial milestones.
- Projected Closing Date: The transaction is subject to customary antitrust reviews and regulatory approvals and is expected to close in the second half of 2026.
Myricx Bio, originally founded in 2019 as a spinout from two of the UK's leading scientific research centers—Imperial College London and the Francis Crick Institute—had previously raised a moderate amount of venture backing. Investors in the company include high-profile life sciences venture funds such as Novo Holdings, Sofinnova Partners, and Cancer Research Horizons. The $1.5 billion transaction represents a highly successful exit for these early backers, validating their investment in Myricx’s alternative payload technology.
The $1.1 billion upfront cash component is particularly significant given that Myricx's assets are currently in preclinical development. It represents one of the largest upfront values paid for a preclinical platform in recent years, highlighting the high premium that big pharma is willing to pay for novel, clinically differentiated ADC platforms that can bypass standard chemotherapeutic payload classes.
What is the NMTi payload and how does it differ from TOPO-1 and tubulin ADC payloads?
The strategic prize of the acquisition is Myricx’s proprietary N-myristoyltransferase inhibitor (NMTi) payload platform. To understand why Novartis paid $1.5 billion for a pipeline whose lead assets have not yet published clinical readouts, one must examine the biochemistry of the payload itself.
The Payload Bottleneck
Today's ADC pipeline is heavily overcrowded with two classic payload classes:
- Tubulin Inhibitors (e.g., MMAE, MMAF, DM1, DM4): These agents halt cell division by disrupting microtubule assembly. They are the payloads behind established ADCs such as Adcetris, Kadcyla, and Padcev.
- Topoisomerase-1 (TOPO-1) Inhibitors (e.g., DXd, SN-38): These agents cause double-stranded DNA breaks during replication. They are the payloads behind the highly successful Enhertu and Trodelvy.
As detailed in our study on Antibody-Drug Conjugate (ADC) Clinical Trials by the Numbers (2026), the extreme popularity of these payloads has created a clinical bottleneck. Standard payloads face two main limitations:
- Resistance Mechanisms: Tumors frequently develop resistance to tubulin and TOPO-1 inhibitors through the upregulation of drug efflux pumps (like P-gp) or alterations in target enzymes.
- Overlapping Toxicities: If a patient progresses on a TOPO-1 ADC (such as Enhertu), treating them with a second TOPO-1 ADC is clinically limited by cumulative toxicities (such as interstitial lung disease or severe neutropenia).
The NMTi Mechanism of Action
N-myristoyltransferase (NMT) is an enzyme that catalyzes the transfer of myristic acid (a 14-carbon saturated fatty acid) to the N-terminal glycine of specific proteins. This modification, known as myristoylation, is essential for directing these proteins to cell membranes, where they participate in vital signal transduction pathways, vesicular trafficking, and oncogenic signaling.
+------------------------------------------------------------+
| NMTi ADC Mechanism of Action |
| |
| [ Antibody ] === ( Linker ) === [ NMTi Payload ] |
| │ |
| ▼ (Binds to Tumor Antigen: B7-H3 or HER2) |
| Internalization into Lysosome |
| │ |
| ▼ (Cleavage & Release of NMTi) |
| Inhibition of N-myristoyltransferase (NMT) |
| │ |
| ▼ |
| Halts Protein Myristoylation (Lipid Modification) |
| │ |
| ▼ |
| Disrupts Membrane Localization of Vital Proteins (Src-family kinases) |
| │ |
| ▼ |
| Induces Apoptosis / Cell Death (Orthogonal to Chemo) |
+------------------------------------------------------------+
By inhibiting NMT, Myricx’s payload disrupts the lipid modification of critical cellular proteins, preventing them from anchoring to the cell membrane. Without membrane localization, these proteins cannot function, leading to rapid cell death.
Because NMT inhibition target-selects an entirely different cellular process than chemotherapy or DNA damage, it offers three distinct clinical advantages:
- No Cross-Resistance: Myricx’s NMTi construct remains highly active in tumor cell lines that have developed resistance to tubulin-disrupting or DNA-damaging payloads.
- Orthogonal Toxicity Profile: In preclinical studies, NMTi ADCs did not induce the severe neutropenia, thrombocytopenia, or pulmonary toxicities associated with standard ADC payloads.
- Bystander Effect Capability: Myricx’s linkers are designed to release a membrane-permeable payload that can diffuse out of the target cell to kill adjacent, antigen-negative tumor cells within the tumor microenvironment (bystander killing), which is crucial for treating heterogeneous tumors.
Scientific Provenance: From Lab Bench to Pharma Acquisition
The biology of NMT was pioneered over several decades of academic research. Professor Ed Tate and his team at Imperial College London, alongside researchers at the Francis Crick Institute, conducted foundational studies showing that NMT expression is elevated in many aggressive cancers, and that pharmacological inhibition of this enzyme halts protein lipid modifications and triggers cell death. Myricx Bio was spun out to commercialize this research, designing linkers that are highly stable in blood circulation but rapidly cleaved inside the acidic environment of lysosomes. This ensures that the potent NMTi payload is only released after the ADC is internalized by the target cancer cell.
Which two lead ADC assets (B7-H3, HER2) does Novartis acquire?
The acquisition adds two lead preclinical ADC assets designed to demonstrate the proof-of-concept for the NMTi payload platform in solid tumors.
1. B7-H3-Targeted NMTi ADC
B7-H3 (CD276) is an immune checkpoint molecule belonging to the B7 family. It is highly overexpressed on the surface of many solid tumors—including prostate cancer, non-small cell lung cancer (NSCLC), esophageal cancer, and pediatric sarcomas—while showing very low expression on healthy tissues. This differential expression makes B7-H3 a highly attractive target for ADC development.
However, B7-H3 is an active competitive battlefield. Daiichi Sankyo's ifinatamab deruxtecan (I-DXd, utilizing a TOPO-1 payload) is currently in Phase 3 trials for small cell lung cancer, and other sponsors are actively advancing their own candidates. Novartis’s acquisition of Myricx’s B7-H3 construct represents a direct bet that its NMTi payload can outperform Daiichi Sankyo's TOPO-1 payload, particularly in patients who have failed prior chemotherapy or other ADC regimens.
The therapeutic rationale in small cell lung cancer is particularly strong because B7-H3 is nearly universally expressed in SCLC tissues. SCLC accounts for approximately 15% of all lung cancer cases and is characterized by rapid growth, early metastasis, and a very poor prognosis (with a five-year survival rate of less than 7%). Most patients relapse rapidly after standard etoposide/platinum chemotherapy, leaving a major unmet clinical need. By bringing a novel payload mechanism to this target, Novartis has the potential to address the rapid disease progression and chemotherapy resistance that characterizes advanced neuroendocrine lung tumors.
2. HER2-Targeted NMTi ADC
HER2 (ERBB2) is the most crowded antigen in the entire ADC registry. As discussed in our ADC access landscape analysis, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has established a dominant market position across HER2-positive and HER2-low breast, gastric, and lung cancers.
Developing a new HER2 ADC faces an exceptionally high regulatory and clinical bar. A new candidate cannot simply show efficacy; it must demonstrate superiority or an improved safety profile over Enhertu. Novartis is positioning its acquired HER2-NMTi asset as a late-line option for patients who have progressed on or developed resistance to Enhertu. If preclinical assays hold true in humans, the NMTi payload should successfully bypass the mechanisms that render Enhertu inactive, providing a viable sequencing option for advanced breast cancer patients.
Why was Novartis the last big-pharma ADC holdout given its radioligand platform?
Novartis’s late entry into the ADC category is a reflection of a deliberate strategic choice. While rivals built ADC pipelines, Novartis focused its resources on establishing leadership in Radioligand Therapy (RLT).
Through its landmark acquisitions of Advanced Accelerator Applications ($3.9 billion in 2017) and Endocyte ($2.1 billion in 2018), Novartis secured Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for prostate cancer and Lutathera (lutetium Lu 177 dotatate) for neuroendocrine tumors. (For a registry-level view of this modality, see our Radioligand Therapy Clinical Trials by the Numbers (2026) analysis).
The Radioligand vs. ADC Platform Strategy
Novartis’s strategic hesitation was driven by several considerations:
- Manufacturing Barriers: Radioligands require a complex, highly specialized logistics network involving short-lived isotopes (such as Lutetium-177 or Actinium-225) that must be manufactured and delivered to patients within hours. Novartis invested hundreds of millions of dollars to build dedicated RLT manufacturing facilities in Indianapolis, Millburn, and Zaragoza, creating a moat that rivals could not easily copy.
- Platform Focus: Novartis believed that by dominating a single, highly specialized modality (RLT), it could capture high-margin oncology revenue without competing directly in the crowded ADC space.
- The Spin-Off Context: Novartis spent several years restructuring its operations, culminating in the spinoff of its generic division, Sandoz, in late 2023. As detailed in our Novartis Portfolio Dossier (Post-Sandoz Spinoff), this spin-off refocused Novartis as a pure-play, high-margin innovative medicine developer.
The Financial Legacy of the Sandoz Spinoff
The spinoff of Sandoz on October 4, 2023, was a structural watershed for Novartis. As a standalone generics and biosimilars business, Sandoz accounted for nearly $10 billion in annual sales but significantly dragged down Novartis's gross and operating margins due to the commodity price pressure of generics. By parting ways with Sandoz in a tax-neutral transaction, Novartis CEO Vas Narasimhan refocused the company's capital allocation.
Instead of funding high-volume, low-margin generic manufacturing plants, Novartis could deploy its massive free cash flow into high-barrier platforms. The cash generated from operations, combined with the proceeds of Sandoz's debt-refinancing payments, created a substantial capital cushion. This financial flexibility directly funded the 2026 M&A spree, enabling Novartis to make bold bets on early-stage innovative platforms like Myricx.
The Necessity of ADC Entry
By 2026, however, the commercial reality of oncology M&A forced a change in strategy. The clinical success of ADCs has made the modality an essential component of any major oncology franchise.
For Novartis, entering the ADC space is not an admission of RLT failure, but rather a complementary expansion. Many solid-tumor targets are not suitable for radioligands due to radiation exposure limits in healthy tissues, whereas ADCs can be safely administered. Additionally, Novartis is actively exploring targeted alpha-emitters (such as Actinium-225 based candidates like Ac-225-PSMA-617) in early clinical trials. By combining its RLT platform with the newly acquired Myricx ADC platform, Novartis can offer a comprehensive portfolio of precision-oncology therapies, positioning itself as a key partner for oncology clinics.
How does this deal fit Novartis's 2026 deal spree?
The Myricx acquisition is the latest in a series of major transactions executed by Novartis in 2026. After completing its post-Sandoz consolidation, Novartis has deployed its substantial cash reserves to rebuild its clinical pipeline.
To track the scale of this activity, we compiled the major pipeline-building transactions Novartis struck in the first half of 2026 (note that not all are oncology assets, and the Orionis agreement is a collaboration rather than an outright acquisition):
| Date of Announcement | Target Company | Total Deal Value (Potential) | Primary Asset / Platform | Therapeutic Indication |
|---|---|---|---|---|
| March 2026 | Pikavation Therapeutics (Synnovation) | Up to ~$3.0 billion ($2.0B upfront + up to $1.0B milestones) | SNV4818 (pan-mutant-selective PI3Kα inhibitor) | PIK3CA-mutant breast cancer |
| March 2026 | Excellergy | Up to $2.0 billion | Next-generation anti-IgE biologic (potential Xolair successor) | Allergy / immunology |
| June 2026 | Orionis Biosciences (collaboration) | $40M upfront + up to $1.4 billion in milestones | Allo-Glu molecular-glue platform | Undruggable targets (multiple) |
| July 2026 | Myricx Bio | Up to $1.5 billion ($1.1B upfront + up to $400M milestones) | NMTi ADC platform (B7-H3, HER2) | Solid tumors |
This transaction spree occurs against the backdrop of a broader biopharma M&A boom. As tracked in our aggregate Biopharma M&A Deals by the Numbers (2026) report, there were 33 biotech acquisitions valued at $1 billion or more globally in the first half of 2026 alone, compared to only 26 in the entire year of 2025. Facing patent cliffs on blockbusters like Entresto and Promacta, Novartis is aggressively using M&A to secure its next generation of growth.
In addition to Novartis's deals, the broader industry has seen major consolidations:
- Johnson & Johnson acquired Ambrx Biopharma in early 2024 for $2.0 billion to secure its synthetic amino acid conjugation technology.
- AstraZeneca acquired Gracell Biotechnologies in early 2024 for $1.2 billion to expand its cell therapy capabilities.
- AbbVie finalized its $10.1 billion acquisition of ImmunoGen in early 2024, acquiring the folate receptor alpha-targeted ADC Elahere.
This intense competition for platforms underscores the strategic necessity of the Myricx transaction. Rather than waiting for clinical assets to mature—where acquisition costs frequently exceed $10 billion—Novartis is buying early, securing a foundational platform at a lower price point with the goal of developing its own proprietary candidates internally.
What does Novartis's ADC entry mean for the crowded ADC competitive landscape?
Novartis’s entry into the ADC space shifts the competitive dynamics for established players. The table below compares the ADC platform strategies of the major global biopharma players:
| Biopharma Player | Primary ADC Acquisition/Platform | Key Approved/Late-Stage Assets | Primary Payload Focus |
|---|---|---|---|
| Pfizer | Seagen ($43B, 2023) | Padcev, Adcetris, Tivdak | Tubulin inhibitors (MMAE) |
| AstraZeneca | Daiichi Sankyo Partnership | Enhertu, Datroway | TOPO-1 inhibitors (DXd) |
| AbbVie | ImmunoGen ($10.1B, 2023) | Elahere | Tubulin inhibitors (DM4) |
| Gilead Sciences | Immunomedics ($21B, 2020) | Trodelvy | TOPO-1 inhibitors (SN-38) |
| Novartis | Myricx Bio ($1.5B, 2026) | B7-H3-NMTi, HER2-NMTi | NMT inhibitors (NMTi) |
Novartis’s acquisition strategy is highly differentiated from its peers. Instead of paying a premium for a late-stage or marketed asset (such as AbbVie's $10.1 billion purchase of ImmunoGen to acquire Elahere), Novartis chose a mid-sized, platform-focused transaction. By acquiring Myricx for $1.5 billion, Novartis secured a first-in-class payload technology that it can combine with its own internal library of monoclonal antibodies.
The success of the Myricx deal will depend on how quickly Novartis can advance the lead preclinical B7-H3 and HER2 assets into Phase 1 clinical trials. If the NMTi payload demonstrates a superior safety profile and clear efficacy in humans, Novartis will have successfully established a highly competitive, differentiated ADC platform. If clinical trials replicate the toxicities of standard chemotherapies, Novartis will find itself trailing its competitors in a crowded modality.
Furthermore, Novartis's move will likely trigger further consolidation. With the last major pharma holdout now committed to the ADC space, mid-sized biotechs with alternative payload platforms (such as bicyclic peptides, site-specific conjugation methods, or novel DNA-damaging payloads) will see their strategic value rise as remaining players seek to secure their own entry points.
FAQs
Is the Novartis-Myricx deal $1.5B upfront or total?
The $1.5 billion figure represents the total potential deal value. The transaction is structured with $1.1 billion in cash paid upfront at closing, with the remaining $400 million structured as milestone payments contingent upon the successful completion of specific clinical development, regulatory approvals, and commercial launch goals.
Are Myricx's NMTi-ADC assets in clinical trials yet?
No. As of the announcement in July 2026, Myricx's lead assets targeting B7-H3 and HER2 are in late-stage preclinical development. Novartis’s immediate operational priority will be submitting Investigational New Drug (IND) applications to the FDA to initiate Phase 1 clinical trials to evaluate the safety, tolerability, and pharmacokinetics of these constructs in human subjects.
How does NMTi compare to existing ADC payloads like deruxtecan or vedotin?
Deruxtecan (a TOPO-1 inhibitor) and vedotin (a tubulin-disrupting agent) are chemotherapy-based payloads that target cell replication and division. Myricx's NMTi payload inhibits N-myristoyltransferase (NMT), blocking the lipid modification required to anchor critical proteins to the cell membrane. Because NMTi targets an entirely different cellular process, it remains active in cancer cells that have developed resistance to standard chemotherapy payloads and avoids the typical side effects associated with systemic chemotherapy release.
Will this acquisition close in 2026?
Yes. The transaction is expected to close in the second half of 2026, subject to customary regulatory approvals, antitrust reviews under the Hart-Scott-Rodino (HSR) Act in the U.S., and equivalent foreign investment clearances in the UK.
What role did Novo Holdings play in the transaction?
Novo Holdings, the investment arm of the Novo Nordisk Foundation, was a major investor in Myricx Bio: it co-led the company's £90 million ($114 million) Series A round with Abingworth in mid-2024, alongside Cancer Research Horizons, the British Business Bank, and Eli Lilly (the 2019 seed was co-led by Sofinnova Partners and Brandon Capital). That funding was earmarked to advance the NMTi payload platform toward the clinic. The acquisition by Novartis represents a major financial return for Novo Holdings, which has been actively expanding its venture investments in UK and European biotech.
Where will the clinical development of Myricx's assets be managed?
While Novartis will fully integrate Myricx's technology into its global oncology development franchise, the initial preclinical and early translational research teams are expected to maintain close ties to the academic clusters in London. This hybrid model allows Novartis to leverage the scientific expertise of the spinout founders while utilizing its own vast global clinical operations network to execute phase 1-3 trials.
Who are the primary competitors developing B7-H3 ADCs?
The most advanced competitor targeting B7-H3 is Daiichi Sankyo with its candidate ifinatamab deruxtecan (I-DXd, DS-7300), which is currently in Phase 3 registrational development for small cell lung cancer (SCLC) under a major development deal with Merck. Additionally, companies like MacroGenics are developing B7-H3 targeted molecules (such as vobramitamab duocarmazine), and several early-stage biotechs have active preclinical programs. Novartis's acquisition of Myricx enters a highly competitive B7-H3 landscape, but its NMTi payload is the only one utilizing lipid-modification inhibition, representing a highly differentiated approach.
Sources
- Novartis AG. Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with novel NMTi payload platform (official press release, July 6, 2026). Novartis Media Releases
- Myricx Bio. Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform. Myricx Bio Announcements
- Novo Holdings. Novo Holdings portfolio company Myricx Bio agrees to be acquired by Novartis. Novo Holdings News
- U.S. Food and Drug Administration (FDA). FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. FDA Approved Drugs
- U.S. Food and Drug Administration (FDA). FDA approves lutetium Lu 177 vipivotide tetraxetan for progressive metastatic castration-resistant prostate cancer. FDA Pluvicto Approval
- U.S. National Library of Medicine. A Study of Ifinatamab Deruxtecan (I-DXd) in Subjects with Relapsed Small Cell Lung Cancer (SCLC). ClinicalTrials.gov NCT05280470
- BioPharma Dive. Novartis to acquire ADC developer Myricx in a deal worth up to $1.5B. BioPharma Dive Oncology
- BioSpace. Novartis drops up to $1.5B for ADC specialist Myricx, continuing cancer spending spree. BioSpace Deals
- STAT News. Pharma goes on a spending spree: Inside the H1 2026 M&A boom. STAT M&A Tracker
